Backround Guidelines for economic analyses of health care technologies require local input data for reimbursement decisions in the countries of Central and Eastern Europe (CEE). The aim of this study was to systematically review and analyse the available empirical studies using the EQ-5D instrument as a measure of the health-related quality of life (HRQoL) in patients with neurological diseases. Methods A systematic literature search was performed up to 1st April 2018 to identify relevant studies in eight selected CEE countries. Original articles reporting on studies of neurological diseases using the EQ-5D instrument were analysed. Results Thirty-six articles, describing the results of 38 samples of patients and a total of 13,005 patients were included in the review. Most studies were from Hungary (44.4%) and none from Romania or Slovakia. EQ-5D utility scores were reported in 33 (91.7%) articles. In multiple sclerosis (MS) being the most represented disease, the average utility scores ranged from 0.49 in Austria to 0.80 in Poland with a weighted average of 0.69. EQ VAS scores for MS ranged from 39 in Czech Republic to 72.0 in Poland, with weighted average of 59.1. MS patients, together with epilepsy and essential tremor patients, estimated their HRQoL among the highest. Conclusions EQ-5D research activity in neurology has been increasing through the years in studied CEE countries. There are clinical areas with the significant social burden, such as a migraine or meningitis, that are completely lacking data, other areas, such as stroke or epilepsy, with very scarce data.
Introduction
Health-related quality of life (HRQoL) is a multi-dimensional concept that includes domains related to physical, mental, and social functioning [1] . HRQoL can be impacted by multiple neurological disorders including epilepsy [2] , multiple sclerosis (MS) [3] , and Parkinson's disease (PD) [4] . It is generally recommended that a generic measure of HRQoL should be used alongside a disease-specific measure(s) to address both clinical and broader policy questions [5] . Disease-specific HRQoL instruments include questionnaires such as the MS Quality of Life Inventory (MSQLI) for multiple sclerosis [6] , Parkinson's Disease Questionnaire-39 item version (PDQ-39) [7] and Newcastle Stroke-specific Quality of Life measure (NEWSQOL) [8] . Generic measures are applicable across a wide range of populations and interventions and enable comparison of HRQoL among them. Commonly used generic status measures are EQ-5D, SF-6D and Health Utility Index (HUI) [9] . One major advantage of these measurement tools is that a 'utility value' (preference based score, reflecting societal valuation) can be attached to each health state description which can then be used to calculate the 'Q' of the quality-adjusted life year (QALY) gain in health economic evaluations. In this paper we focus on the EQ-5D, a standardized instrument for evaluating HRQoL and was developed in the late 1980s by EuroQol Group [10] . The EQ-5D is recommended for use in cost-effectiveness studies in many countries, among them in the United States by the Washington panel on Cost-Effectiveness in Health and Medicine [10] , in the UK by the National Institute for Health and Clinical Excellence [11] as well as in Poland by Polish HTA Guidelines by The Agency for Health Technology Assessment and Tariff System (AOTMiT) [12] . Rencz et al. [13] reported increasing use of EQ-5D throughout CEE: the spread of health technology assessment activities by countries seems to be reflected in the increasing number of EQ-5D studies. A wide range of clinical areas was covered, of which diseases of the circulatory system (20% of studies), nervous system (16%), musculoskeletal system and connective tissue (15%), and endocrine, nutritional and metabolic conditions (14%) were the most frequent. The authors called for the improvement in informed use and methodological quality of reporting. The need for such call was confirmed in a review by Zrubka et al. [14] , where the authors identified incomplete reporting impacting the usefulness of data for economic analysis in a systematic literature review and meta-analysis of musculoskeletal and connective tissue diseases. The increase in the number of published studies on the use of EQ-5D is noticed also in cardiovascular diseases [15] .
Our objective was to determine the HRQoL of neurological patients across diseases in selected CEE countries measured by EQ-5D and analyse the quality of reporting.
Methods

EQ-5D questionnaire
The EQ-5D instrument is based on a descriptive system that defines health in five dimensions: mobility, self-care, usual activities (e.g., work, household or leisure activities), pain/discomfort, and anxiety/depression [10] . In the EQ-5D-3L version, each dimension has three response categories: no problems, some problems, and severe problems. The descriptive system defines a total of 243 possible states with 2 additional states (dead and unconscious). In 2011, EuroQol Group launched a five-level version of the EQ-5D questionnaire-the EQ-5D-5L [16] . The descriptive system is complemented by a visual analogue scale (EQ VAS) with 0 representing 'worst imaginable health' and 100 representing 'best imaginable health'. The EQ-5D outcomes include: (i) health profiles, derived from the descriptive system (ii) self-rated health status, derived from the EQ VAS, and (iii) health state utility score (value set or tariffs), derived from preference weights for all possible (EQ-5D-3L: 243; EQ-5D-5L 3125) health states. Value sets have been developed in several countries using either the time trade-off (TTO) valuation technique or the visual analogue scale (VAS) valuation technique. Another EQ-5D version (EQ-5D-Y) for use by children and adolescents was introduced by the EuroQol Group in 2009 [17] .
Literature search
This study builds on a systematic review of EQ-5D studies in selected CEE countries performed in 2015, with a special focus on nervous system diseases (International Classification of Diseases ICD-10, Chapter VI: G00-G99) [13] . The search was updated applying the same methodology for the period between 1st July 2015 and the 1st April 2018 and covered following databases: PubMed, EMBASE, Web of Science, CINAHL, PsychINFO and the Cochrane Library. EuroQol Group database was also searched to identify additional studies. The search strategy used the combination of the following terms: (euroqol OR euro qol OR Eq. 5d OR Eq. 5d OR eq-5d) AND (Austria* OR Bulgaria* OR Hungar* OR Czech OR Poland OR Polish OR Romania* OR Slovak* OR Sloven*). Building on their countryexpertise, authors have conducted a hand-search for papers not included in indexed electronic databases. No language restrictions were imposed. The PRISMA guidelines for reporting systematic reviews were followed (Fig. 1) .
Selection of publications
Full-text journal articles meeting the following criteria were included in the review: (i) the study was conducted on patients with neurological diseases (ii) the study population originated from selected CEE countries-Austria, Bulgaria, the Czech Republic, Hungary, Poland, Romania, Slovakia or Slovenia or was a multi-centre study including at least one of the previously stated countries (iii) the article reported an EQ-5D outcome on more than two patients, and (iv) the study represented an original research. Multi-country studies were excluded if country-level EQ-5D data from the index countries were not reported. Duplicate reports from the same study population were avoided. Quantitative analysis included all the articles where either utility score or EQ VAS score or both were reported.
Data extraction and analysis
A Microsoft Excel spreadsheet was developed to extract the data from identified studies. General characteristics of the studies (year of publication, language, and source of funding), study methodology (data collection, study setting, design and duration), study population (demographics, diagnosis, and disease duration), version of the EQ-5D questionnaire applied (EQ-5D-3L or EQ-5D-5L), value sets used and type of EQ-5D outcomes (utility scores, health profiles, and EQ VAS scores) were collected. In two studies [18, 19] two different samples of patients were described (distinct diseases, patients from different countries). Therefore the number of samples included amounts to 38. In the quantitative synthesis pooled mean values and standard deviations for study demographics and EQ-5D index scores were calculated.
Results
Main characteristics of the studies
Thirty-six papers met all the inclusion criteria ( Fig. 1) . Most of the studies (n = 16) were conducted in Hungary [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] , followed by Poland (n = 10) [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] and Austria (n = 5) [44] [45] [46] [47] [48] . We found three studies from Czech Republic [49] [50] [51] two studies from Slovenia [52, 53] , one study [19] from Bulgaria and no studies from Slovakia or Romania (Annex 1 Supplementary table 1). Most of the papers (n = 23) were published in English, while 13 studies in national languages: seven studies in Hungarian [18, 21, 23, [27] [28] [29] 32] , three in Polish [37, 40, 41] , two in Czech [49, 50] and one in German [46] . The earliest study was published in 2004 and was performed in Austria [46] . From 2014 onwards, the number of papers per year has tripled. Most of the studies (n = 14) focused on determining HRQoL of patients with MS [30, 33, 34, 37-39, 42-44, 46-48, 51, 53] or PD (9) [20-24, 27, 29, 31, 45] , while the research on other diseases was rare and consisted of: three studies in neuropathic pain (NP) [26, 49, 50] , two in stroke [35, 36] , two in Duchenne Muscular Dystrophy (DMD) [18, 19] , and one study per disease area including epilepsy [32] , essential tremor [25] , dystonia [28] and carpal tunnel syndrome [52] . In one more study, a mix of patients with extrapyramidal diseases (PD 58%, essential tremor, dystonia) was included [40] . In another one-patients with spasticity, mainly in course of MS (85%), were studied [41] . Most of the studies were cross-sectional (N = 14) or prospective cohort (N = 15) by design. Only one randomized control trial was identified [41] . The sample sizes and patients' characteristics (mean age, disease duration) varied widely across studies and diseases (Table 1) .
All the studies reported sample size and only one study [52] did not report the age of the patients. For almost one quarter of the samples (10 out of 38) there were no data on disease duration and in five studies the gender structure of the patients included in the study was not reported.
EQ-5D results reported by the studies
The data on EQ VAS, EQ-5D index and health profiles were reviewed as reported in Table 2 .
In 21 studies EQ-5D version used was reported, including seven with EQ-5D-5L version, twice simultaneously with EQ-5D-3L [35, 36] . The EQ-5D-5L questionnaire was also used in the only study in children. In twenty-nine studies, both EQ VAS and EQ-5D index score were reported. In two [27, 42] and three studies [20, 40, 47] only EQ VAS score and the EQ-5D index was reported, respectively. The tariff used for estimation of index scores was specified for 21 samples only (UK-14, Polish-5, 1 Slovenian-2 and European-1). In two studies only descriptive system results were reported [29, 41] . In two further studies, only changes in the health status of the patients, but not the absolute values, were presented [44, 52] .
In Fig. 2 , the scores across diseases are reported as EQ VAS and EQ-5D index. In UK-TTO value set the lowest valued state is at − 0.594 and the highest at 1.000 which is the scale for index values used in the figure. In most papers reporting two independent measures of HRQoL (except paper on DMD), patients' subjective health status assessment (EQ VAS) gave lower scores regarding their HRQoL than the assessment reflecting the preferences of the society (EQ-5D index). However, the two measures should not be directly compared as they reflect different preferences: while the index value reflects how good or bad the health state is according to the preferences of the general population of a country/region (using most often the time trade-off valuation method), whilst EQ VAS reflects patient's subjective values of a health state (indicated on a health thermometer). The highest mean EQ-5D index utility score was reported in patients with epilepsy (of note, this was the youngest adult patient group) and the lowest in patients with dystonia (one sample involving 40 patients). Eleven studies (five in PD, two in NP and single studies in MS, stroke, essential tremor and dystonia) researched the effect of various treatments on HRQoL (see Fig. 3 ) [18, 19, 21-23, 25, 26, 32, 47, 52, 53] . All the treatment studies reported increased mean HRQoL with the exception of treatment with generic ropinirole as a replacement for originator medication for PD [24] . In two studies [20, 35] no treatment was applied; two subsequent measurements were only used for the purpose of assessing the measurement characteristics of the instrument. Next, it is evident that the biggest increase in EQ-5D index score was reported in studies with the lowest initial EQ-5D index score [23, 27, 28] , with a study by Herceg et al. [25] being an exception to that, as significant improvement in EQ-5D index score was reported in spite of rather high initial value.
Discussion
The number of studies using EQ-5D has been increasing in the observed countries, especially since 2012. Although some diseases such as PD and MS have been rather widely explored, the research in certain disease areas is concentrated in single countries-for example, PD in Hungary and MS in Poland and Austria. This can be explained by a specific interest of different research groups in different countries, as well as by non-systematic approach towards HRQoL research in neurological diseases. Namely, a scarcity of HRQoL studies on the highly-prevalent and important disease areas such as neuropathy, stroke, epilepsy, meningitis, and migraine can be observed.
Methodological issues are also the potential negative consequences of the non-systematic approach to HRQoL research. In five out of 36 studies (14% of the studies) the reported EQ-5D index score had to be excluded due to the inappropriate estimation method used. In two studies [38, 41] the EQ-5D mean score for each dimension was calculated as the sum of response scores on this dimension, divided by the number of patients resulting in a value between 1 and 3 and between 1 and 15 for the total EQ-5D score. In the other two studies [37, 42] the utility score had a value of 8.05 and 2.2, respectively, which is beyond the normative range in which the maximum score is 1 indicating perfect health. The EuroQol organization provides clear guidelines [54] that should be closely followed by researchers and also considered as minimum criteria by the journal editors and reviewers in the process of the manuscript assessment.
Among the diseases studied in more than one paper, MS patients estimated their own HRQoL the highest, compared to patients with other nervous system diseases. However, we find important to note that for the interpretation of the EQ-5D results it is definitely not sufficient to rely only on the diagnosis, but further characteristics of the sample (e.g., age, disease duration, gender rate, rate of patients receiving disease modifing treatments) and the measure used (e.g., 3L versus 5L, value set applied for the calculation of the index score) should be highly considered. As expected, EQ-5D index and EQ VAS scores varied based on the stage of the disease as well as patient characteristics and treatment protocol. Unfortunately, EQ-5D data were not sufficiently stratified by these variables and consequently, it was not possible to obtain further insight through a meta-analysis. Measuring the impact of caring for people on informal caregivers (family members or friends providing help on a voluntary basis for the patient for everyday acivities, including for instance personal care, household activities and supervision if needed) can add substantial knowledge about the burden of the disease from the societal perspective. However, it remains unclear whether EQ-5D is the optimum measure of the impact of caregiving on the HRQoL of carers due to its focus on physical health. There was only one study in our systematic review [18] that included informal carers and even then, the number of carers was low. In estimating the health gains related to an intervention, ignoring the effect of improving the health of one member of the caregiver/child dyad may lead to an underestimation of the utility gained. This may be particularly true for infants/young children and their caregivers. The results of the studies [55] confirm that there appears to be a strong relationship between the EQ VAS scores of the children and their caregivers. The issue has clearly been understudied and demands more research and further consideration.
One of the strengths of our paper, in comparison to previous systematic reviews, is the engagement of the researchers from involved countries, who supported the electronic database search with hand searches in local scientific journals [33, 43, 48, 51] . Some limitations also need mentioning. As the study builds on a systematic review of EQ-5D studies in selected CEE countries [12] and was initiated in April 2018, it uses International Classification of Diseases ICD-10 and not ICD-11 which was released in June 2018. Nevertheless, we think that using the ICD-10 for papers published before 2018 is a rational approach. Our search strategy could miss those publications in which the EQ-5D was not specifically mentioned in the title, abstract or keywords [33, 43, 48, 51] .
Since the EQ-5D is a key measure in health technology assessments supporting reimbursement decisions, authors of publications are encouraged to indicate the name of the EQ-5D tool used among the keywords. It would be worth considering also to include EQ-5D in the system of Medical Subject Headings (MeSH) to enable systematic reviews. One frequent limitation of the included studies is the lack of EQ-5D descriptive part results, preventing the insight into the health dimensions of patients. A small number of studies per disease deprived us of comparative insight into HRQoL between patient groups/treatments. In one-third of the studies, the samples were smaller than 50 patients. The concentration of specific disease research to a single country made cross-country comparisons of HRQoL impossible. Furthermore, not all the studies used the same value set to estimate EQ-5D index scores. The question is whether it is better to use nation-specific value sets for local decision making or common algorithm across all studies to increase the comparability of the studies. Currently country-specific EQ-5D value set is available only in Poland (for both the 3L and 5L) and Slovenia (for the 3L) in the region, thus the UK values set is the most widely used as a proxy. In further studies, the possibilities of using a common value set in CEE countries need to be explored and we suggest to present the most relevant results both with local and international value sets to facilitate comparisons with the literature on the long term.
Inter-country collaborations and joint research planning should be encouraged to efficiently expand health state utility data availability for highly prevalent and costly areas of neurological diseases (such as neuropathy, stroke, epilepsy, meningitis, and migraine). Such a research can promote and facilitate cost-effectiveness studies in the region to strengthen the basis for decision making in health care. The joint research plan and HRQoL methodological support and training could assure the coordination of measurement in a comparable and methodologically correct way. Without coordinated approach, the health outcomes will continue to be scattered and incomparable. 
Compliance with ethical standards
Conflict of interest DG and VPR are members of the EuroQol Group, a not-for-profit organization that develops and distributes instruments that assess and value health. Other authors reported no conflict of interest.
